anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pregnancy Exposure Registry: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment. To report a pregnancy or obtain information about the registry, visit www.mycophenolateREMS.com or call 1-800-617-8191. 

Risk Summary: Use of mycophenolate mofetil (MMF) during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of multiple congenital malformations in multiple organ systems [see Human Data]. Oral administration of mycophenolate to rats and rabbits during the period of organogenesis produced congenital malformations and pregnancy loss at doses less than the recommended clinical dose (0.01 to 0.05 times the recommended clinical doses in kidney and heart transplant patients) [see Animal Data]. 

Consider alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of mycophenolate mofetil should be discussed with the pregnant woman.

The estimated background risk of pregnancy loss and congenital malformations in organ transplant populations is not clear. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data:Human Data: A spectrum of congenital malformations (including multiple malformations in individual newborns) has been reported in 23 to 27% of live births in MMF exposed pregnancies, based on published data from pregnancy registries. Malformations that have been documented include external ear, eye, and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system. 

Based on published data from pregnancy registries, the risk of first trimester pregnancy loss has been reported at 45 to 49% following MMF exposure.

Animal Data: In animal reproductive toxicology studies, there were increased rates of fetal resorptions and malformations in the absence of maternal toxicity. Oral administration of MMF to pregnant rats from Gestational Day 7 to Day 16 produced increased embryofetal lethality and fetal malformations including anophthalmia, agnathia, and hydrocephaly at doses equivalent to 0.015 and 0.01 times the recommended human doses for renal and cardiac transplant patients, respectively, when corrected for BSA. Oral administration of MMF to pregnant rabbits from Gestational Day 7 to Day 19 produced increased embryofetal lethality and fetal malformations included ectopia cordis, ectopic kidneys, diaphragmatic hernia, and umbilical hernia at dose equivalents as low as 0.05 and 0.03 times the recommended human doses for renal and cardiac transplant patients, respectively, when corrected for BSA.
Following administration of NMBA, participants received a single intravenous (i.v.) bolus of Sugammadex at 2 mg/kg as determined utilizing participant ABW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
Patients receive trifluridine/tipiracil PO BID and talazoparib tosylate PO QD on days 1-5. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.
NEW MATERIAL:A pyroglutamic acid derivative expressed by formula I or salt of said derivative (R is nitrogen-containing saturated heterocyclic ring group of five-membered ring containable S; X is single bond or -CO-; Y is -O- or -NH-; n is 1 or 2). EXAMPLE:An N-{(R)-(-)-thiazolidine-4-carbonyl}-pyroglutamic acid benzyl.hy- drochloric acid salt. USE:Useful as remedy for amnesia having strong prolyl endopeptitase inhibiting activity. Capable of oral and parenteral administration. PREPARATION:Carboxylic acid expressed by formula II is reacted with a com pound expressed by formula III (A is hydroxyl group or amino) in the presence of condensation agent to afford the compound expressed by formula I. As the condensation agent, e.g., N,N'-dicyclohexylcarbodiimide is used.
A veterinary preparation for use in the treatment of mastitis caused by penicillin-sensitive organisms comprises a suspension of procaine penicillin G in a gel consisting of at least one lithium p  salt of a long-chain aliphatic acid containing from 10 to 28 carbon atoms in the molecule, e.g. lithium stearate, and a mineral oil, which is liquid paraffin or a mixture of liquid paraffin with white or soft yellow paraffin.  The preparations contain from 0.1 to 10, and preferably 0.6 to 1, per cent of the lithium salt and, e.g., 3.5 per cent procaine penicillin G.  They may also contain an aluminium salt of the above mentioned aliphatic acids and a therapeutic salt of streptomycin or dihydrostreptomycin, e.g. the sulphate.  In one example, lithium stearate is triturated with liquid paraffin and the mixture heated to 210 DEG  C. with stirring until it becomes clear. The temperature is then allowed to fall, but not below 150 DEG  C. for at least one hour, and the cooled gel is passed through a homogenizer to form a mobile liquid.  To this liquid procaine penicillin G is added and triturated until no particles of the penicillin salt exceed 100 microns in size.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to derivatives of pyridazine of the general formula (I)   where R 1  means phenyl or pyridyl group that can be substituted by 1-3 substituents taken among halogen atom and lower alkoxy-groups; R 2  means phenyl group that can be substituted at position 4 by lower alkoxy-group, lower alkylthio-group, lower alkylsulfinyl or lower alkylsulfonyl group and by 1 or 2 substituents at other positions taken among halogen atom, lower alkoxyl groups, lower alkylthio groups, lower alkylsulfinyl groups and lower alkylsulfonyl groups; R 3  means hydrogen atom, lower alkoxyl- group, halogenated lower alkyl group, lower cycloalkyl group, phenyl, pyridyl or phenyloxy-group that can be substituted by 1-3 substituents taken among halogen atoms, lower alkyl groups, lower alkoxyl groups, carboxyl group, lower alkoxycarbonyl groups, nitro-group, amino-group, lower alkylamino groups and lower alkylthio groups; piperidino-group, piperidinyl group, piperazino-group or morpholino-group that can be unsubstituted or substituted by lower alkyl group; aminocarbonyl group that can be unsubstituted or substituted by benzyl group; lower alkylcarbonyl group; or piperazinocarbonyl group that can be unsubstituted or substituted by lower alkylyl group; A means linear or branched lower alkylene or lower alkenylene group comprising 1-6 carbon atoms; or A can mean a direct linkage when R 3  means lower cycloalkyl or halogenated lower alkyl group; X means oxygen or sulfur atom under condition that the following combinations are excluded: R 1  and R 2  mean 4-methoxyphenyl group; X means oxygen atom; A means a direct linkage and R 3  means hydrogen atom or 2-chloroethyl group; or their salts. Indicated compounds are inhibitors of interleukin-1 β producing. Except for, invention relates also to medicinal agent that is inhibitor of production of interleukin-1 β, medicinal agent used for prophylaxis and treatment of patients with arthritis and method for treatment of patient with arthritis. EFFECT: valuable medicinal properties of compounds. 8 cl, 4 tbl, 172 ex
Research into the efficacy of photobiomodulation therapy (PBMT) in reducing inflammation has been ongoing for years, but standards for irradiation methodology still need to be developed. This study aimed to test whether PBMT stimulates in vitro human peripheral blood mononuclear cells (PBMCs) to synthesize pro-inflammatory cytokines, including chemokines. PBMCs were irradiated with laser radiation at two wavelengths simultaneously (λ = 808 nm in continuous emission and λ = 905 nm in pulsed emission). The laser radiation energy was dosed in one dose as a whole (5 J, 15 J, 20 J) or in a fractionated way (5 J + 15 J and 15 J + 5 J) with a frequency of 500, 1,500 and 2,000 Hz. The surface power densities were 177, 214 and 230 mW/cm2, respectively. A pro-inflammatory effect was observed at both the transcript and protein levels for IL-1β after PBMT at the energy doses 5 J and 20 J (ƒ=500 Hz) and only at the transcript level after application of PBMT at energy doses of 20 J (ƒ= 1,500; ƒ=2,000 Hz) and 5 + 15 J (ƒ=500 Hz). An increase in CCL2 and CCL3 mRNA expression was observed after PBMT at 5 + 15 J (ƒ=1,500 Hz) and 15 + 5 J (ƒ=2,000 Hz) and CCL3 concentration after application of an energy dose of 15 J (frequency of 500 Hz). Even though PBMT can induce mRNA synthesis and stimulate PBMCs to produce selected pro-inflammatory cytokines and chemokines, it is necessary to elucidate the impact of the simultaneous emission of two wavelengths on the inflammatory response mechanisms.
1,273,004. Transparent lipsticks. YARDLEY OF LONDON Inc. 19 June, 1969 [25 June, 1968], No. 31152/69. Heading A5B. Cosmetic colouring sticks adapted for application to the lips comprise a polyamide resin which is solid at ambient temperature, a dye soluble in organic solvents and a solvent for the polyamide which solvent is an organic lipophilic surfactant having an HLB number of 3-6. The resin is preferably a resin sold under the Trade Marks Versalon or Versamid, or the trade names Scope or Emrez. The solvent may be an ethoxylated straight chain unsaturated fatty alcohol, an ethoxylated branched chain fatty alcohol, a polyhydric alcohol fatty acid ester, an ethoxylated unsaturated fatty acid amide, an alkanolamine unsaturated fatty acid amide, a hydroxy fatty acid ether of a fatty alcohol or ethoxylated lanolin alcohol, in particular diethoxy oleyl alcohol, triethoxyoleyl alcohol, pentaethoxy lanolin alcohols, triethoxy hexadecyl alcohol, ethoxylated isostearyl alcohol, diethoxy cetyl alcohol, propylene glycol monoricinoleate, glyceryl monoricinoleate, sorbitan monooleate, sorbitan sesquioleate, isostearic acid esters, triglycerol monolaurate, triglycerol monooleate, triglycerol dioleate, hexaglycerol monooleate, hexaglycerol dioleate, decaglycerol dioleate, sorbitan trioleate, polyglycerol oleate, diethoxy linoleic amide, pentaethoxy lanolin ether, diethanolamine unsaturated fatty acid amides or oleyl sarcosine. Preferably the solvent for the polyamide is also a solvent for the dye. The compositions may also include cosmetic excipients, diluents and couplers such as oleyl alcohol, and solvents for the dye e.g. tetrahydrofurfuryl alcohol or diethoxytetrahydrofurfuryl alcohol.
Our society is aging much faster than it was before, and this phenomenon demands concerted action to optimize geriatric care. Presentations, clinical features, and management decision making are distinct between older adults and the general population, and to enhance care quality, there remains unmet needs for undergraduate geriatric education. Among all geriatric syndromes that clinically matter, frailty is particularly instrumental, serving as the overarching phenotype that connects other geriatric conditions and predisposes individuals to adverse outcomes. However, understandings for frailty, or "literacy for frailty" is often poor among healthcare professionals, and misidentification, terminology confusion, and uncertainty surrounding the care of frail older adults, are not uncommon. This lack of frailty literacy undoubtedly contributes to the suboptimal geriatric care patients receive. We therefore propose a rationally designed, concise, and structured program for eliciting medical students' motivation for understanding frailty during their undergraduate period. Our increasing-frailty-literacy program includes 7 modules, accommodating the terminology, integrative pathogenesis, epidemiology of frailty, appropriate screening and identification tool selection, prognostication and patient communication, and individualization of treatment strategies. In combination with digital technologies and hands-on practice opportunities, we believe that our curriculum can promote medical students' learning efficacy for frailty and improve geriatric care for the current generation.
Methylphenidate hydrochloride tablets, USP contains methylphenidate hydrochloride, a CNS stimulant. It is available as tablets of 5 mg, 10 mg, and 20 mg strengths for oral administration.

Methylphenidate hydrochloride is methyl α-phenyl-2-piperidineacetate hydrochloride, and its structural formula is:

Methylphenidate hydrochloride USP is a white, odorless, fine crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77 g/mol.

Methylphenidate hydrochloride tablets, USP contains the following inactive ingredients: colloidal silicon dioxide, lactose anhydrous, magnesium stearate, and microcrystalline cellulose.
TARA is comprised of 12 weekly classes delivered in a group format by two trained facilitators with approximately 8-15 participants. The 90 minute sessions are designed to promote skills for autonomic regulation, attention modulation, emotion regulation and cognitive control.
Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
Includes patients with a predicted procedural mortality of 12% or higher. The high risk registry arm of the study is powered to show superiority of safety of treatment with the MitraClip compared to mitral valve surgery. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip implant.
FIELD: medicine. SUBSTANCE: remedy has dry substance of medicinal plant crushed to particles of 5-20 mm in size. Large monoapplicator, small monoapplicator and monoapplicator for launching action program are applied. Method involves applying therapeutic or prophylactic program including treatment with the above mentioned biocorrectors acting upon reflexogenic zone receptors. The total treatment course is 5-10 sessions long. EFFECT: wide range of functional applications. 12 cl, 2 tbl
Phenylacetylglutamine (PAGln), a gut metabolite is substantially elevated in heart failure (HF). The increase of PAGln in plasma is associated with atrial fibrillation (AF), and contributes to AF pathogenesis. However, the role of PAGln in AF with HF remains uncertain. Therefore, this study aimed to determine the effect of PAGln on AF after HF. Thoracic aortic coarctation (TAC) created overpressure-induced HF mice for 4 weeks. Histopathology, biochemical, echocardiographic for assessment of cardiac function, and electrophysiological examination of several electrophysiological indexes (ERP, SNRT, and the occurrence rate of AF) were performed at the end of the HF mice model. We found that plasma PAGln levels were significantly elevated in PAGln-treated HF mice and that PAGln aggravated maladaptive structural remodeling and electrical remodeling, which aggravated the vulnerability of AF, shortened the ERP duration, prolonged the SNRT, increased the occurrence rate of AF in HF mice. Mechanistically, PAGln exacerbated ROS accumulation and increased the levels of phosphorylated PLB and CAMK II. Overall, PAGln played a vital role in promoting the occurrence of AF in HF mice by activating the CAMK II signaling pathway.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety data below were collected from 1492 women who received doxorubicin at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 (AC) every 3 weeks for 4 cycles for the adjuvant treatment of axillary lymph node positive breast cancer. The median number of cycles received was 4. Selected adverse reactions reported in this study are provided in Table 1. No treatment-related deaths were reported in patients on either arm of the study.

* Includes pooled data from patients who received either AC alone for 4 cycles, or who were treated with AC for 4 cycles followed by 3 cycles of CMF
There is an increasing trend in the burden of renal cell carcinoma (RCC) globally. Although different therapies like tyrosine kinase inhibitors, ablative therapy, surgery, and immunotherapy have been suggested for RCC, they are not cost-effective. The present study will be conducted as an open-label, phase Ib/II study consisting of a dose-escalation stage followed by a cohort expansion stage. The trial will be conducted in the medical centers affiliated to the Tabriz University of Medical Sciences. Patients 18 years or older presenting with histologically confirmed RCC with a clear-cell component, that progressed to the advanced or metastatic stage will be recruited. The dose-escalation stage will determine the schedule and maximum tolerated dose (MTD) and/or recommended Expansion Stage dose of sodium pentaborate pentahydrate. One oral sodium pentaborate pentahydrate capsule once daily will be considered for evaluation in 21-day treatment cycles: 500 mg, 1000 mg, and 1500 mg. Subjects will accrue in escalation cohorts of 3-6 subjects using a "3 plus 3" design and dosing will begin at the 500 mg dose level of sodium pentaborate pentahydrate. During this stage, the decision to open a new cohort will be made when all subjects have been followed for at least 21 days following the first dose of sodium pentaborate pentahydrate(defined as the dose-limiting toxicity (DLT) Evaluation Period). In the dose-expansion stage, we will further assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of NaB in RCC using the recommended dose and schedule as determined in the dose-escalation stage. The primary objectives for the dose-escalation stage and dose-expansion stage will be to determine the maximum tolerated dose (MTD) and/or recommended dose and schedule for the subsequent expansion stage and to evaluate the preliminary efficacy of the sodium pentaborate pentahydrate by estimating the objective response rate, respectively. The investigator will assess each subject continuously to evaluate for potential new or worsening adverse events.
Participants in the Morning Group will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. They will also have time-based energy intake goals of 70% of kcal within the first 6 hrs of the eating window and 30% of kcal within the last 6 hrs of the eating window (a morning-loaded energy distribution).
Chronic kidney disease (CKD) is a major public health concern that has reached epidemic proportions. Hypertension is a leading modifiable risk factor for cardiovascular disease (CVD) and end-stage kidney disease, yet 50-70% of adults with CKD fail to achieve blood pressure (BP) control to \<130/80 mmHg. A key process linking high systolic BP (SBP) to CVD is vascular endothelial dysfunction, which is due in part to increased reactive oxygen species and decreased nitric oxide. Nitric oxide is also critical in the regulation of renal blood flow, which is intimately related to blood pressure and vascular function. High-resistance inspiratory muscle strength training (IMST) is a novel lifestyle intervention involving repeated inhalations against a resistive load using a hand-held device. This study will test whether high-resistance IMST (75% of maximal inspiratory pressure \[75% PImax\]; 30 breaths \[5 min\]/day, 6 days \[30 min\]/week) vs. Sham training (15% PImax) reduces resting systolic blood pressure in midlife and older adults (\>50 years) with moderate-to-severe CKD and inadequately controlled hypertension. Changes in 24-hr systolic blood pressure and endothelial function (brachial artery flow-mediated dilation) are secondary outcomes. Innovative translational techniques will be used to provide mechanistic insight, including serum incubation in endothelial cell culture, metabolomics analysis, endothelial cell collections, and assessment of renal blood flow by magnetic resonance imaging.
Junel21 and Junel Fe 28 are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.

* The authors' best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason.

** This term represents “typical” couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason.

*** N/A-Data not available.
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for treating ocular hypertension.  <P>SOLUTION: The invention generally relates to a pharmaceutical industry, especially a pharmaceutical industry for producing an ophthalmic composition. More particularly, the invention relates to a pharmaceutical industry for producing an ophthalmologic composition for treating ocular hypertension. The advantage in technology status of the invention comprises realizing synergistic effects of each component without causing an antagonism among components for lowering intraocular pressure. The pharmaceutical composition for treating ocular hypertension comprises a pharmacologically acceptable amount of dorzolamide, a pharmacologically acceptable amount of timolol and a pharmacologically acceptable amount of brimonidine.  <P>COPYRIGHT: (C)2009,JPO&INPIT